172 related articles for article (PubMed ID: 27513300)
61. Role and regulation of CD1d in normal and pathological B cells.
Chaudhry MS; Karadimitris A
J Immunol; 2014 Nov; 193(10):4761-8. PubMed ID: 25381357
[TBL] [Abstract][Full Text] [Related]
62. Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.
Walzer T; Dalod M; Vivier E; Zitvogel L
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S49-59. PubMed ID: 16187940
[TBL] [Abstract][Full Text] [Related]
63. Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.
Choo QWW; Koean RAG; Chang SC; Chng WJ; Chan MC; Wang W; Er JZ; Ding JL
Immunol Cell Biol; 2020 Feb; 98(2):138-151. PubMed ID: 31837284
[TBL] [Abstract][Full Text] [Related]
64. Navigating the Role of CD1d/Invariant Natural Killer T-cell/Glycolipid Immune Axis in Multiple Myeloma Evolution: Therapeutic Implications.
Papoutselis M; Spanoudakis E
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):358-365. PubMed ID: 32234294
[TBL] [Abstract][Full Text] [Related]
65. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.
Ebeling SB; Ivanov R; Hol S; Aarts TI; Hagenbeek A; Verdonck LF; Petersen EJ
Br J Haematol; 2003 Jun; 121(5):721-9. PubMed ID: 12780786
[TBL] [Abstract][Full Text] [Related]
66. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
Hsieh YC; Kirschner K; Copland M
Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
[TBL] [Abstract][Full Text] [Related]
67. Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.
Lameris R; de Bruin RC; van Bergen En Henegouwen PM; Verheul HM; Zweegman S; de Gruijl TD; van der Vliet HJ
Immunology; 2016 Sep; 149(1):111-21. PubMed ID: 27312006
[TBL] [Abstract][Full Text] [Related]
68. Protein kinase C isoforms in normal and leukemic neutrophils: altered levels in leukemic neutrophils and changes during myeloid maturation in chronic myeloid leukemia.
Balasubramanian N; Advani SH; Zingde SM
Leuk Res; 2002 Jan; 26(1):67-81. PubMed ID: 11734305
[TBL] [Abstract][Full Text] [Related]
69. Advances in immunotherapy of chronic myeloid leukemia CML.
Held SA; Heine A; Mayer KT; Kapelle M; Wolf DG; Brossart P
Curr Cancer Drug Targets; 2013 Sep; 13(7):768-74. PubMed ID: 23906051
[TBL] [Abstract][Full Text] [Related]
70. [Biological features of dendritic cells derived from chronic myeloid leukemia cells in vitro].
Tong XM; Jin J; Qian WB; Meng HT; Xue YQ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 34(4):348-52, 357. PubMed ID: 16059984
[TBL] [Abstract][Full Text] [Related]
71. Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia.
Westermann J; Kopp J; Körner I; Richter G; Qin Z; Blankenstein T; Dörken B; Pezzutto A
Bone Marrow Transplant; 2000 May; 25 Suppl 2():S46-9. PubMed ID: 10933188
[TBL] [Abstract][Full Text] [Related]
72. Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer.
Nam GH; Lee EJ; Kim YK; Hong Y; Choi Y; Ryu MJ; Woo J; Cho Y; Ahn DJ; Yang Y; Kwon IC; Park SY; Kim IS
Nat Commun; 2018 Jun; 9(1):2165. PubMed ID: 29867097
[TBL] [Abstract][Full Text] [Related]
73. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.
De Santo C; Salio M; Masri SH; Lee LY; Dong T; Speak AO; Porubsky S; Booth S; Veerapen N; Besra GS; Gröne HJ; Platt FM; Zambon M; Cerundolo V
J Clin Invest; 2008 Dec; 118(12):4036-48. PubMed ID: 19033672
[TBL] [Abstract][Full Text] [Related]
74. Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment.
Yao D; Lai J; Lu Y; Zhong J; Zha X; Huang X; Liu L; Zeng X; Chen S; Weng J; Du X; Li Y; Xu L
Front Immunol; 2023; 14():1078118. PubMed ID: 36742315
[TBL] [Abstract][Full Text] [Related]
75. Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Harada I; Sasaki H; Murakami K; Nishiyama A; Nakabayashi J; Ichino M; Miyazaki T; Kumagai K; Matsumoto K; Hagihara M; Kawase W; Tachibana T; Tanaka M; Saito T; Kanamori H; Fujita H; Fujisawa S; Nakajima H; Tamura T
Sci Rep; 2021 Sep; 11(1):18046. PubMed ID: 34508131
[TBL] [Abstract][Full Text] [Related]
76. CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV.
Miura S; Kawana K; Schust DJ; Fujii T; Yokoyama T; Iwasawa Y; Nagamatsu T; Adachi K; Tomio A; Tomio K; Kojima S; Yasugi T; Kozuma S; Taketani Y
J Virol; 2010 Nov; 84(22):11614-23. PubMed ID: 20810727
[TBL] [Abstract][Full Text] [Related]
77. γδ T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia.
Molina-Aguilar R; Montiel-Cervantes LA; Anguiano-Peñaloza SV; Lezama R; Vela-Ojeda J; Reyes-Maldonado E
Arch Med Res; 2020 Apr; 51(3):194-203. PubMed ID: 32113783
[TBL] [Abstract][Full Text] [Related]
78. Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
Harrington P; Dillon R; Radia D; McLornan D; Woodley C; Asirvatham S; Raj K; Curto-Garcia N; Saunders J; Kordasti S; Harrison C; de Lavallade H
Br J Haematol; 2022 Sep; 198(6):1011-1015. PubMed ID: 35802024
[TBL] [Abstract][Full Text] [Related]
79. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.
Claudiani S; Apperley JF; Deplano S; Khorashad J; Foroni L; Palanicawandar R; Perry R; Milojkovic D
Am J Hematol; 2016 Nov; 91(11):E480-E481. PubMed ID: 27467708
[No Abstract] [Full Text] [Related]
80. Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity.
Berger MG; Bourgne C
Adv Exp Med Biol; 2019; 1139():171-185. PubMed ID: 31134501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
